VALHALLA, N.Y. (September 9, 2025) – In honor of Westchester Medical Center’s extensive experience in using the cutting-edge technology GammaTile® to treat patients with brain tumors, GT Medical Technologies (a medical device company focused on improving the lives of patients with brain tumors) has officially designated Westchester Medical Center as a GammaTile® Center of Excellence. The hospital was one of the earliest adopters of the technology in the United States, allowing Westchester Medical Center to become one of only 5 institutions nationally to use the technology on 50 or more patients.
The GammaTile® Center of Excellence designation places Westchester Medical Center among an elite group of institutions recognized for advancing brain tumor treatment through the use of GammaTile® therapy, an FDA-approved technology that combines surgical tumor removal with immediate, localized radiation therapy. GammaTile® is approved for use in patients with newly diagnosed malignant brain tumors and recurrent tumors, including glioblastomas, brain metastases, and meningiomas.
The treatment uses a small bioabsorbable collagen tile embedded with radiation seeds, which is placed directly at the site of a tumor immediately after its surgical removal. By eliminating the traditional delay between surgery and radiation therapy, GammaTile® delivers targeted radiation to any remaining cancer cells when they are most vulnerable, reducing the risk of recurrence while minimizing damage to healthy brain tissue.
“With GammaTile® therapy, we’re able to deliver treatment to brain tumor patients with much greater precision and fewer side effects,” said Simon Hanft, MD, FAANS, Section Chief of Neurosurgical Oncology at Westchester Medical Center. “Compared to surgery and radiation given separately, GammaTile® offers the potential for faster recovery, fewer cognitive side effects, less hair loss, and fewer hospital visits—enhancing both patient outcomes and the patient experience.”
To make an appointment or referral for a patient who may be a candidate for GammaTile® treatment, call 914-493-7000 or visit https://www.wmchealth.org/find-a-doctor/.
About Westchester Medical Center Health Network
The Westchester Medical Center Health Network (WMCHealth) is the pre-eminent provider of integrated health care in New York’s Hudson Valley region, serving nearly 2.5 million residents across more than 6,000 square miles. A 1,700-bed healthcare system headquartered in Valhalla, New York, including nine hospitals on seven campuses and 60 ambulatory care sites, WMCHealth is home to the region’s only Level I (adult and pediatric) trauma center and the only Academic Medical Center between New York City and Albany. The Network employs more than 13,000 people and has nearly 3,000 attending physicians – seeing nearly 300,000 unique patients every year, and is the State’s largest Medicaid provider north of New York City, serving 1 in 3 Medicaid patients in the region. WMCHealth also features Level II and Level III trauma centers, a nationally renowned pediatric hospital that is the region’s only acute care children’s hospital and leading pediatric hospital across the country, the region’s only Level IV NICU, the region’s only Organ Transplant Center, several community hospitals, and dozens of specialized institutes and centers. The Network also includes Comprehensive and Primary Stroke Centers, Burn Center, skilled nursing, and one of the largest mental health systems in New York State. For more information about WMCHealth, visit WMCHealth.org or follow WMCHealth on Facebook or Instagram.
About GT Medical Technologies, Inc.
GT Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care.
About GammaTile
GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within—placed into the surgical cavity at the time of tumor removal—GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are most vulnerable to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue.
Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit gammatile.com and follow @GammaTile on Facebook, Instagram, LinkedIn and X.
